Hanmi Science Co Ltd
008930
Company Profile
Business description
Hanmi Science Co Ltd is a Korea-based holding company. The company through its subsidiaries manufactures and distributes pharmaceutical products. The company offers prescription drugs such as neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, smoking cessation aid, diabetes, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, among others.
Contact
214 Muha-ro Paltan-myeon
Gyeonggi-do
Hwaseong
KORT: +82 24109114
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2025
Employees
486
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,239.18 | 13.55 | 0.16% |
| DAX 40 | 24,308.78 | 68.89 | 0.28% |
| Dow JONES (US) | 47,456.29 | 249.17 | 0.53% |
| FTSE 100 | 9,653.82 | 8.20 | 0.09% |
| HKSE | 26,433.70 | 273.55 | 1.05% |
| NASDAQ | 23,590.98 | 386.12 | 1.66% |
| Nikkei 225 | 50,512.32 | 1,212.67 | 2.46% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,860.17 | 68.48 | 1.01% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,996.94 | 46.63 | 1.18% |